Ensign Peak Advisors
BEAM icon

Ensign Peak Advisors’s Beam Therapeutics BEAM Stock Holding History

Ensign Peak Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Sell
5,861
-850
-13% -$25.7K ﹤0.01% 1376
2026
Q1 		$160K Hold
6,711
– – ﹤0.01% 1415
2025
Q4 		$186K Sell
6,711
-14,300
-68% -$365K ﹤0.01% 1350
2025
Q3 		$510K Sell
21,011
-8,100
-28% -$161K ﹤0.01% 1378
2025
Q2 		$495K Hold
29,111
– – ﹤0.01% 1556
2025
Q1 		$569K Hold
29,111
– – ﹤0.01% 1514
2024
Q4 		$722K Hold
29,111
– – ﹤0.01% 1485
2024
Q3 		$713K Hold
29,111
– – ﹤0.01% 1498
2024
Q2 		$682K Hold
29,111
– – ﹤0.01% 1502
2024
Q1 		$962K Sell
29,111
-1,469
-5% -$45.8K ﹤0.01% 1349
2023
Q4 		$832K Hold
30,580
– – ﹤0.01% 1483
2023
Q3 		$735K Hold
30,580
– – ﹤0.01% 1419
2023
Q2 		$976K Buy
30,580
+2,250
+8% +$73K ﹤0.01% 1279
2023
Q1 		$867K Buy
28,330
+2,800
+11% +$111K ﹤0.01% 1352
2022
Q4 		$998K Buy
25,530
+11,800
+86% +$529K ﹤0.01% 1160
2022
Q3 		$654K Sell
13,730
-60,757
-82% -$3.47M ﹤0.01% 1322
2022
Q2 		$2.88M Buy
74,487
+66,047
+783% +$2.63M 0.01% 685
2022
Q1 		$484K Hold
8,440
– – ﹤0.01% 1562
2021
Q4 		$673K Sell
8,440
-18,594
-69% -$1.59M ﹤0.01% 1487
2021
Q3 		$2.35M Hold
27,034
– – ﹤0.01% 1020
2021
Q2 		$3.48M Hold
27,034
– – 0.01% 807
2021
Q1 		$2.16M Sell
27,034
-93,273
-78% -$8.87M ﹤0.01% 1073
2020
Q4 		$9.82M Buy
120,307
+54,489
+83% +$2.68M 0.02% 422
2020
Q3 		$1.62M Buy
65,818
+37,366
+131% +$927K ﹤0.01% 1084
2020
Q2 		$797K Sell
28,452
-6,154
-18% -$133K ﹤0.01% 1347
2020
Q1 		$623K Buy
+34,606
New +$752K ﹤0.01% 1328

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Ensign Peak Advisors's BEAM Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Beam Therapeutics (BEAM) stake by 13% in Q2 2026, selling an estimated $25.7K and leaving 5,861 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

Ensign Peak Advisors first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $9.82M in Q4 2020. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Ensign Peak Advisors held 5,861 shares of Beam Therapeutics worth $201K as of Q2 2026.
  • Ensign Peak Advisors sold 850 Beam Therapeutics shares in Q2 2026, an estimated $25.7K.
  • Beam Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1376 holding.
  • Ensign Peak Advisors first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Beam Therapeutics position peaked at $9.82M in Q4 2020.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.